NEW YORK (GenomeWeb News) — The National Cancer Institute wants the scientific community to help it identify new priorities for biomarker discovery and validation research that could be conducted using resources of the Early Detection Research Network.
The information NCI receives may be used to help it identify future directions for the National Institutes of Health-funded EDRN, which is aimed at discovering, developing, and validating biomarkers for cancer risk assessment, early detection, and early diagnosis and prognosis. The network provides infrastructure and an environment that supports translational research by encouraging collaborations among basic scientists, population-based scientists, and clinically experienced scientists.
Now, NCI is seeking information from members of the scientific community, health professionals, biotech and pharmaceutical industries, and patient advocates.
The EDRN has four main components, including: Biomarker Developmental Laboratories focused on discovery, development, and characterization of new biomarkers; Biomarker Reference Laboratories that serve as a resource for clinical and lab validation of biomarkers; Clinical Epidemiology and Validation Centers that conduct early phases of clinical and epidemiological research on the application of biomarkers; and a Data Management and Coordinating Center that provides statistical, logistics, and informatics support, and develops the theoretical statistical approaches for biomarker analysis.
NCI is seeking information about promising research directions that could stimulate or accelerate biomarker development, and for transdisciplinary research collaborations. NCI also seeks information about strategies for developing or validating biomarkers, ideas about how the EDRN could partner with private industry and foundations, information about industry support, and funding and validation priorities.
More information about the request for information is available on NIH's website.